Leap therapeutics and beigene announce exclusive option and license agreement, co announces $27 mln equity financing

Leap therapeutics and beigene announce exclusive option and license agreement for dkn-01 and leap announces $27 million equity financing.leap therapeutics inc - initiation of combination studies of leap's dkn-01 with beigene's anti-pd-1 antibody tislelizumab planned.leap therapeutics inc - beigene granted option to develop and commercialize leap's dkn-01 in asia pacific region, excluding japan.leap therapeutics inc - will receive an upfront cash payment of $3 million from beigene.leap therapeutics - eligible to get payments from beigene based on achievement of some milestones for total deal value of upto $132 million.
LPTX Ratings Summary
LPTX Quant Ranking